ClinicalTrials.gg
CompletedNCT02253160CMNCUpdated Sep 24, 2015Results posted

An Evaluation of the Spectra Optia CMNC Collection Procedure

An interventional study of Spectra Optia CMNC and COBE Spectra MNC in Healthy Apheresis Donors and Mononuclear (MNC) Cell Donors, sponsored by Terumo BCT. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Terumo BCT (part of Terumo Corporation) · Not applicable and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this prospective, randomized, cross-over, multi-center study is to evaluate the performance of the Spectra Optia Apheresis System's CMNC Collection Procedure, compared to the COBE Spectra Apheresis System's MNC Procedure in mobilized healthy donors. Subject safety will be evaluated beginning with mobilization, throughout the collection procedure and for the day following the last collection.

Read the detailed description

This is a prospective, randomized, cross-over, multi-center study to evaluate the performance of the Spectra Optia system's CMNC Collection Procedure, compared to the COBE Spectra system's MNC Procedure in mobilized healthy donors.

Up to 60 subject may be consented to meet the the enrollment target of 20 complete subjects. Eligible subjects will be randomized to receive either the Spectra Optia CMNC or the COBE Spectra MNC collection procedure first, followed by the opposite on the following day.

Study participation will be up to 14 days: a 7-day screening period, four days for mobilization, one day for the first MNC collection with additional dose of mobilization, one day for the second MNC collection, and safety follow-up the following day.

Subject safety will be evaluated beginning with mobilization, throughout the collection procedure and for the day following the second collection.

02

Conditions studied

  • Healthy Apheresis Donors
  • Mononuclear (MNC) Cell Donors

Keywords

  • MNCs
  • Mononuclear Cells
  • Apheresis
  • Spectra Optia
03

In context

Lead sponsor

Terumo BCT is the lead sponsor of 14 studies on the registry; none are open to participants now.

First submitted after Terumo BCT became part of Terumo Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 and ≤ 50 years of age
  2. Healthy blood donor criteria as defined by the American Associate of Blood Banks (AABB)

    a) Note: Subjects who are deferred from volunteer donations because of travel restrictions, piercings or tattoos may participate in the study

  3. Adequate dual peripheral venous access
  4. Acceptable prescreening laboratory results prior to MNC mobilization as specified below:

    a) WBC 3,500 - 10,800/µL

    b) Hematocrit 38% - 56%

    c) 150,000 - 400,000/µL

    d) Coagulation tests:

    i. PT 9.0 - 13.0 seconds

    ii. 23.4 - 41.8 seconds

    e) Serum electrolytes:

    i. Potassium 3.6 - 5.1 mmol/L

    ii. Serum Calcium 8.5 mg/dL - 10.3 mg/dL

    f) Renal function: Serum creatinine ≤ 1.5 mg/dL

    NOTE: up to two laboratory results may fall out of the ranges listed above if, in the judgment of the investigator, they do not constitute a significant risk to the subject.

  5. Liver function: (ALT) \< 1.5 times the
  6. Willing to avoid pregnancy until at least 48 hours following last G-CSF injection

    1. If male, be willing to use a condom during sexual relations with a female partner until 48 hours following the last G-CSF injection
    2. If female and of , be willing to use a medically acceptable until 48 hours following the last G-CSF injection
  7. Given written

Exclusion criteria

Exclusion Criteria:

  1. Previous MNC collection failure
  2. Known or condition that prevents the use of anticoagulants
  3. Known hypersensitivity or condition that prevents the use of G-CSF
  4. Known hemoglobinopathy including sickle cell trait or disease
  5. History of use in the past week or anticipated need for lithium
  6. Concurrent enrollment in another clinical study that could impact the results or participation in this study
  7. Active infection or any serious underlying medical condition that contraindicates apheresis
  8. Women who are pregnant or lactating
  9. Known history of significant head trauma
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Spectra Optia CMNC first, then COBE Spectra MNC

    Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.

    Device: Spectra Optia CMNC · Device: COBE Spectra MNC · Drug: Granulocyte-colony stimulating factor (G-CSF)

  • Experimental
    COBE Spectra MNC first, then Spectra Optia CMNC

    COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.

    Device: Spectra Optia CMNC · Device: COBE Spectra MNC · Drug: Granulocyte-colony stimulating factor (G-CSF)

Interventions

  • DeviceSpectra Optia CMNC

    The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.

    Also known as: Spectra Optia Apheresis System CMNC collection procedure

  • DeviceCOBE Spectra MNC

    It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.

    Also known as: COBE Spectra Apheresis System MNC collection procedure

  • Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.

    Also known as: Mobilization Procedure

06

What researchers measure

Primary outcomes

  1. CD34+ Collection Efficiency (CE1 %)

    The primary endpoint is the CD34+ cell collection efficiency (CE) associated with the Mononuclear Cell (CMNC) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the CMNC collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

    Time frame: within 5 minutes upon completion of procedure

Secondary outcomes

  1. CD34+ Collection Efficiency (CE2 %)

    Comparison of collection efficiencies associated with the CMNC Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor blood counts immediately before and blood product blood counts immediately after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

    Time frame: within 5 minutes upon completion of procedure

  2. MNC Collection Efficiency (CE1%)

    Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

    Time frame: within 5 minutes upon completion of procedure

  3. CD34+ Per kg of Body Weight

    Time frame: within 5 minutes upon completion of procedure

  4. MNC Product Contamination/Purity (%) - Hematocrit (%)

    Time frame: within 5 minutes upon completion of procedure

  5. MNC Product Contamination/Purity (%) - Granulocyte Concentration (10^3/mL)

    Time frame: within 5 minutes upon completion of procedure

  6. MNC Product Contamination/Purity (%) - Platelet Concentration (10^3/µL)

    Time frame: within 5 minutes upon completion of procedure

  7. MNC Product Contamination/Purity (%) - Platelet Collection Efficiency (CE1 %)

    Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for platelets. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

    Time frame: within 5 minutes upon completion of procedure

  8. MNC Blood Product Volume (mL)

    The produced unit of MNCs collected into the blood bag.

    Time frame: within 5 minutes upon completion of procedure

  9. Purity of Plasma Collected for Laboratory Processing of MNC Product - Platelet Concentration in Plasma (10^3/µL)

    A small amount of plasma typically used for processing was collected in a sub-set of collection procedures.

    Time frame: within 5 minutes upon completion of procedure

  10. Procedure Time (Minutes)

    Time frame: within 5 minutes upon completion of procedure

  11. MNC Collection Efficiency (CE2%)

    Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE2 is a measurement of device performance calculated using donor blood counts immediately before and blood product counts immediately after the collection procedure and does not average the donor pre- and post-collection counts. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

    Time frame: within 5 minutes upon completion of procedure

  12. MNC Product Contamination/Purity - RBC Concentration (10^6/µL)

    Time frame: within 5 minutes upon completion of procedure

Other outcomes

  1. Device Deficiencies

    Any time a device or disposable does not function as described in the Operator's Manual or Package Insert, a Device Deficiency must be reported. This includes those instances wherein Operator Error led to a malfunction/deficiency. A device deficiency is any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer. Device malfunctions and device incidents should be reported in the same manner.

    Time frame: 24-hours after last collection procedure

  2. Post-collection Platelet Loss in Subject

    The percent change from pre-collection platelet count to post-collection subject platelet count.

    Time frame: 24-hours after last collection procedure

07

Results

Posted Sep 24, 2015

Participant flow

Subjects were recruited from the specialized donor population of blood centers from August 2014 through January 2015.

Participant flow — Overall Study
MilestoneLead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNC
Started11210
Completed11210
Not completed000

Outcome measures

PrimaryCD34+ Collection Efficiency (CE1 %)

The primary endpoint is the CD34+ cell collection efficiency (CE) associated with the Mononuclear Cell (CMNC) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the CMNC collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · percent
CD34+ Collection Efficiency (CE1 %)
percentTreatment Assignment 1Treatment Assignment 2
Spectra Optia87.7 ± 20.1881.4 ± 10.24
COBE Spectra66.6 ± 20.2665.8 ± 6.40
SecondaryCD34+ Collection Efficiency (CE2 %)

Comparison of collection efficiencies associated with the CMNC Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor blood counts immediately before and blood product blood counts immediately after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · percent
CD34+ Collection Efficiency (CE2 %)
percentTreatment Assignment 1Treatment Assignment 2
Spectra Optia64.7 ± 14.6159.6 ± 6.17
COBE Spectra47.0 ± 14.8650.2 ± 4.20
SecondaryMNC Collection Efficiency (CE1%)

Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · percent
MNC Collection Efficiency (CE1%)
percentTreatment Assignment 1Treatment Assignment 2
Spectra Optia CE162.06 ± 17.22063.75 ± 18.900
COBE Spectra CE145.46 ± 6.48348.58 ± 14.685
SecondaryCD34+ Per kg of Body Weight
Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · cells/kg
CD34+ Per kg of Body Weight
cells/kgTreatment Assignment 1Treatment Assignment 2
Spectra Optia5.14 ± 3.7563.75 ± 1.506
COBE Spectra3.50 ± 2.7323.68 ± 1.546
SecondaryMNC Product Contamination/Purity (%) - Hematocrit (%)
Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · % of red blood cells
MNC Product Contamination/Purity (%) - Hematocrit (%)
% of red blood cellsTreatment Assignment 1Treatment Assignment 2
Spectra Optia Hematocrit6.1 ± 2.123.7 ± 0.95
COBE Spectra Hematocrit4.5 ± 1.545.7 ± 1.71
SecondaryMNC Product Contamination/Purity (%) - Granulocyte Concentration (10^3/mL)
Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · cells*10^3/mL
MNC Product Contamination/Purity (%) - Granulocyte Concentration (10^3/mL)
cells*10^3/mLTreatment Assignment 1Treatment Assignment 2
Spectra Optia51.689 ± 35.597063.338 ± 44.9682
COBE Spectra83.792 ± 58.949170.944 ± 72.4223
SecondaryMNC Product Contamination/Purity (%) - Platelet Concentration (10^3/µL)
Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · cells*10^3/µL
MNC Product Contamination/Purity (%) - Platelet Concentration (10^3/µL)
cells*10^3/µLTreatment Assignment 1Treatment Assignment 2
Spectra Optia3724.9 ± 962.422022.9 ± 674.91
COBE Spectra2857.4 ± 467.443736.0 ± 1200.88
SecondaryMNC Product Contamination/Purity (%) - Platelet Collection Efficiency (CE1 %)

Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for platelets. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · percent
MNC Product Contamination/Purity (%) - Platelet Collection Efficiency (CE1 %)
percentTreatment Assignment 1Treatment Assignment 2
Spectra Optia28.7 ± 14.0823.5 ± 8.62
COBE Spectra27.9 ± 9.1930.3 ± 9.85
SecondaryMNC Blood Product Volume (mL)

The produced unit of MNCs collected into the blood bag.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · mL
MNC Blood Product Volume (mL)
mLTreatment Assignment 1Treatment Assignment 2
Spectra Optia144.8 ± 32.99141.3 ± 30.82
COBE Spectra140.8 ± 28.36137.7 ± 28.64
SecondaryPurity of Plasma Collected for Laboratory Processing of MNC Product - Platelet Concentration in Plasma (10^3/µL)

A small amount of plasma typically used for processing was collected in a sub-set of collection procedures.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · cells*10^3/µL
Purity of Plasma Collected for Laboratory Processing of MNC Product - Platelet Concentration in Plasma (10^3/µL)
cells*10^3/µLTreatment Assignment 1Treatment Assignment 2
Spectra Optia32.5 ± 30.418.7 ± 5.86
COBE Spectra147.5 ± 4.95179.3 ± 72.47
SecondaryProcedure Time (Minutes)
Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · minutes
Procedure Time (Minutes)
minutesTreatment Assignment 1Treatment Assignment 2
Spectra Optia153.8 ± 30.90151.4 ± 27.55
COBE Spectra151.1 ± 31.92146.7 ± 27.35
Other pre-specifiedDevice Deficiencies

Any time a device or disposable does not function as described in the Operator's Manual or Package Insert, a Device Deficiency must be reported. This includes those instances wherein Operator Error led to a malfunction/deficiency. A device deficiency is any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer. Device malfunctions and device incidents should be reported in the same manner.

Time frame:
24-hours after last collection procedure
Reported as:
Number · events
Device Deficiencies
eventsSpectra OptiaCOBE Spectra
Device Deficiencies10
Other pre-specifiedPost-collection Platelet Loss in Subject

The percent change from pre-collection platelet count to post-collection subject platelet count.

Time frame:
24-hours after last collection procedure
Reported as:
Mean · percent change
Post-collection Platelet Loss in Subject
percent changeTreatment Assignment 1Treatment Assignment 2
Spectra Optia27.2 ± 9.8823.9 ± 8.04
COBE Spectra27.2 ± 9.4230.7 ± 6.18
SecondaryMNC Collection Efficiency (CE2%)

Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE2 is a measurement of device performance calculated using donor blood counts immediately before and blood product counts immediately after the collection procedure and does not average the donor pre- and post-collection counts. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · percent
MNC Collection Efficiency (CE2%)
percentTreatment Assignment 1Treatment Assignment 2
Spectra Optia CE250.99 ± 16.59052.98 ± 17.528
COBE Spectra CE237.77 ± 5.29739.72 ± 13.972
SecondaryMNC Product Contamination/Purity - RBC Concentration (10^6/µL)
Time frame:
within 5 minutes upon completion of procedure
Reported as:
Mean · RBC*10^6/µL
MNC Product Contamination/Purity - RBC Concentration (10^6/µL)
RBC*10^6/µLTreatment Assignment 1Treatment Assignment 2
Spectra Optia RBC Concentration1.029 ± 0.47400.526 ± 0.1990
COBE Spectra RBC Concentration0.653 ± 0.27860.857 ± 0.2501

Adverse events

Collected over AEs were captured per protocol from the first dose of G-CSF until final follow up, which was typically 1 day after the last CMNC Collection Procedure for a total of 7 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-collection—0/23 (0%)22/23 (95.7%)
Spectra Optia—0/23 (0%)13/23 (56.5%)
COBE Spectra—0/22 (0%)16/22 (72.7%)
Follow up—0/23 (0%)2/23 (8.7%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPre-collectionSpectra OptiaCOBE SpectraFollow up
back painMusculoskeletal and connective tissue disorders10/231/230/220/23
bone painMusculoskeletal and connective tissue disorders9/230/230/220/23
thrombocytopeniaBlood and lymphatic system disorders0/235/235/221/23
platelet count decreasedInvestigations0/230/235/220/23
fatigueGeneral disorders5/231/230/221/23
hemoglobin decreasedInvestigations2/233/232/220/23
paraesthesiaNervous system disorders1/231/232/220/23
peripheral sensory neuropathyNervous system disorders0/230/231/222/23
palpitationsCardiac disorders0/230/231/220/23
hypoaesthesia oralGastrointestinal disorders0/231/231/220/23

Baseline characteristics

Healthy adult specialized blood donors

Age, Continuous
Age, Continuous(years)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
Mean32 ± NA35.4 ± 7.3234.8 ± 8.4435.0 ± 7.51
Sex: Female, Male
Sex: Female, Male(Participants)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
Female0123
Male111820
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
Hispanic or Latino1121023
Not Hispanic or Latino0000
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American15612
White06410
More than one race0000
Unknown or Not Reported0101
Weight
Weight(kilograms)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
Mean110 ± NA115.23 ± 28.92197.08 ± 26.654107.11 ± 28.124
Height
Height(inches)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
Mean60 ± NA70.8 ± 2.4569.4 ± 4.0669.7 ± 3.83
BMI
BMI(kg/m^2)Lead-in DonorSpectra Optia CMNC First, Then COBE Spectra MNCCOBE Spectra MNC First, Then Spectra Optia CMNCTotal
Mean47.36 ± NA35.82 ± 9.41330.88 ± 6.05034.17 ± 8.579
08

Study locations

2 sites
  • Hoxworth Blood Center
    Cincinnati, Ohio 45267-0055, United States
  • Key Biologics, LLC
    Memphis, Tennessee 38104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2014
First posted
Oct 1, 2014
Start
Sep 2014
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Sep 24, 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02253160
Lead sponsor
Terumo BCT
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Sep 2014
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Sep 24, 2015
Last update
Sep 24, 2015

Study contacts

Raymond Goodrich, PhD
study director · Terumo BCT

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Granulocyte Colony-Stimulating Factor

Start the discussion